RWM
EW icon

Ruedi Wealth Management’s Edwards Lifesciences EW Stock Holding History

Ruedi Wealth Management’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-22
Closed -$2.03K – 403
2024
Q2 		$2.03K Buy
+22
New +$1.95K ﹤0.01% 326

Other funds holding EW

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
Ninety One (UK)
Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return

Ruedi Wealth Management's EW Position: Q3 2024 in Review

Ruedi Wealth Management sold out of Edwards Lifesciences (EW) in Q3 2024, closing a stake of 22 shares — an estimated $2.03K sold.

Ruedi Wealth Management first reported a position in EW in Q2 2024 and held it in 1 quarter. The position peaked at $2.03K in Q2 2024. 1,193 funds tracked by Wall St. Rank hold EW as of Q3 2024.

  • Ruedi Wealth Management reported no remaining Edwards Lifesciences position as of Q3 2024 after selling out during the quarter.
  • Ruedi Wealth Management sold 22 Edwards Lifesciences shares in Q3 2024, an estimated $2.03K.
  • Ruedi Wealth Management first reported a position in Edwards Lifesciences in Q2 2024 and held it in 1 quarter.
  • Ruedi Wealth Management's Edwards Lifesciences position peaked at $2.03K in Q2 2024.
  • 1,193 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q3 2024.

Based on Ruedi Wealth Management's 13F filing for Q3 2024, filed 22 Oct 2024.